<DOC>
	<DOCNO>NCT02241837</DOCNO>
	<brief_summary>The primary objective ass longterm safety CardioKinetix Parachute Implant Delivery System partition left ventricle patient heart failure due ischemic heart disease . This sub-study additional assessment improvement Pressure Volume Loop correspond MSCT allow improve monitoring heart improvement therapy . The PV Loop Substudy study effect Parachute Implant pressure volume functional parameter Left Ventricle .</brief_summary>
	<brief_title>PARACHUTE III Pressure Volume Loop Sub-Study</brief_title>
	<detailed_description>While current therapy heart failure ( include limit : medical management , cardiac resynchronization ICDs ) may represent best treatment available today majority HF patient , medical community recognize pharmacologic therapy optimize nearly extent possible , incremental improvement management HF patient come device base therapy . With background , CardioKinetix develop catheter-based intravascular approach ventricular partition use implantable device . The purpose study assess longterm safety use CardioKinetix Parachute device isolate malfunction portion leave ventricle patient symptoms HF due ischemic heart disease .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Candidates study must meet ALL follow inclusion criterion : 1 . Akinesis dyskinesis due myocardial infarction limit anteroapical region 2 . Subject hospitalized time enrollment . 3 . NYHA Class time enrollment , either : NYHA Class III Ambulatory IV predominant 3month period prior enrollment NYHA Class II diagnose NYHA Class III IV 3month period prior enrollment 4 . LVEF &gt; 15 % â‰¤ 40 % measure echocardiography . 5 . Post LV MI structural heart dysfunction represent LV wall motion abnormality ( WMA ) echocardiography . 6 . Eligible cardiac surgery 7 . Between 18 79 year age ( inclusive ) 8 . Receiving appropriate medical treatment heart failure accord ACC/AHA 2009 Guideline Update Diagnosis Management Chronic Heart Failure Adult three month prior enrollment 9 . Provide write informed consent 10 . Agree protocolrequired followup Candidates exclude study ANY follow condition apply : 1 . Untreated clinically significant coronary artery disease require intervention . 2 . Acute MI ( see MI definition ) within 60 day enrollment patient suspect evolve MI time enrollment 3 . Cardiogenic shock within 72 hour enrollment 4 . Revascularization procedure ( PCI CABG ) within 60 day enrollment 5 . Patient receive pacemaker , ICD , CRT device within 60 day enrollment 6 . History abort sudden cardiac death , patient receive ICD potentially lethal ventricular arrhythmia , VT VF 7 . A known hypersensitivity contraindication aspirin , heparin , warfarin , nitinol ( titanium nickel alloy ) , sensitivity contrast medium , adequately pre medicate . 8 . Aortic valve replacement repair 9 . Blood dyscrasia , history bleed diathesis coagulopathy , hypercoagulable state . 10 . Active peptic ulcer GI bleeding within past 3 month 11 . Patient suffer cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within past 6 month 12 . History Kawasaki 's disease 13 . Patient dialysis expect require hemodialysis within 12 month 14 . Patient chronic liver disease 15 . Impaired renal function place patient risk contrast induce renal failure 16 . Ongoing sepsis , include active endocarditis . 17 . Comorbidities associate life expectancy le 12months factor make echo clinical followup difficult ( permanent address , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>heart failure</keyword>
	<keyword>percutaneous</keyword>
	<keyword>interventional cardiology</keyword>
	<keyword>apical remodeling</keyword>
	<keyword>LV dilatation</keyword>
	<keyword>akinesis</keyword>
	<keyword>dyskinesis</keyword>
	<keyword>myocardial infarction</keyword>
</DOC>